You searched for prescription-drugs | Page 44 of 177

Simulating the Impact of the Drug Price Negotiation Proposal in the Build Back Better Act

Jan 27, 2022

Issue Brief

The Build Back Better Act (BBBA) includes a range of health and other proposals supported by President Biden, including a proposal to allow the federal government to negotiate the price of some prescription drugs covered under Medicare Part B (administered by physicians) and Medicare Part D (retail outpatient drugs). This brief illustrates the potential scope of the drug price negotiation proposal in the BBBA. This analysis is designed to highlight the types of Medicare-covered drugs…

Strategies To Lower Drug Costs Top the Public’s Health Priorities for Congress

Mar 31, 2022

News Release

Against the backdrop of public concern about inflation and rising gas prices, proposals to lower what people pay out-of-pocket for drugs tops the public’s list of health care priorities for Congress, a new KFF Health Tracking Poll finds. Most (55%) of the public say inflation is the biggest problem facing the country. Fewer cite other issues such as the Russian invasion of Ukraine (18%), climate change (6%), the COVID-19 pandemic (6%), and crime (6%). The…

Implications of Potential Federal Medicaid Reductions for Addressing the Opioid Epidemic

May 14, 2025

Issue Brief

Medicaid is the main source of coverage for adults with opioid use disorder and among those receiving treatment services. Most adults with OUD in Medicaid are eligible through Medicaid expansion.

How Does Use of Mental Health Care Vary by Demographics and Health Insurance Coverage?

Mar 24, 2022

Issue Brief

This analysis finds that before the pandemic, millions of adults reporting moderate to severe symptoms of anxiety and/or depression were not receiving treatment. Receipt of mental health treatment was lowest among young adults, Black adults, men, and uninsured people.

Medicare’s Coverage Decision for the New Alzheimer’s Drug and Why It Matters

Jan 14, 2022

Policy Watch

This policy watch discusses the implications of Medicare's preliminary National Coverage Determination for the new Alzheimer's drug, Aduhelm, on the 2022 Medicare Part B premium and the possibility of an adjustment based on the coverage decision. The piece also discusses the implications for Medicare spending and the connection to ongoing policy discussions around prescription drug proposals in the Build Back Better Act.

Mail Order Sales of Prescriptions Drugs by Payer

Mar 5, 2020

State Health Facts Indicator

Number of Mail Order Prescriptions Drugs by Payer

Mar 5, 2020

State Health Facts Indicator

Opioid Overdose Deaths: National Trends and Variation by Demographics and States

Feb 24, 2026

Issue Brief

Opioid overdose deaths fell sharply from 2023 to 2024 (79,358 to 54,045), driven largely by decreases in fentanyl-involved deaths. Even after these declines, deaths remained above 2019, the year before opioid deaths increased sharply during the pandemic.

5 Key Facts on Adolescent Mental Health and Substance Use Disorders

May 11, 2026

Issue Brief

Nineteen percent of adolescents experience moderate to severe anxiety and 2 million have a substance use disorder. This analysis covers the latest data on adolescent mental illness, suicide and drug overdose trends, and access to care.

7 in 10 Medicare Beneficiaries Report That They Did Not Compare Their Coverage Options During a Recent Open Enrollment Period

Oct 13, 2021

News Release

With the Medicare open enrollment period set to begin October 15, a new KFF analysis finds that 7 in 10 beneficiaries (71%) say that they didn’t compare their coverage options during a recent open enrollment season. Twenty-nine percent said they did compare Medicare plans. But not shopping around can have a big impact on enrollees’ coverage and costs. The Centers for Medicare & Medicaid Services (CMS) recommends that beneficiaries review and compare Medicare plans each…

Topics

Policy Research

Polling

Health News

Data & Features

For Media

About

Search

Filter